Smart science to improve lives™
0

Small molecule oncology injectables. Greater formulation confidence.

Small molecule injectable development can bring complex formulation challenges, especially in oncology where API stability, solubility, degradation risk, excipient compatibility and delivery performance all matter. Croda Pharma helps formulation teams advance small molecule injectable development with High Purity and Super Refined™ excipient technologies, specialist formulation support and a broad portfolio of injectable-grade excipients designed to support more confident progress from formulation challenge to delivery.

Speak to an expert
Explore products

Built around small molecule oncology formulation challenges

Small molecule oncology injectables often involve APIs that are difficult to solubilise, sensitive to degradation or dependent on carefully selected excipient combinations. Croda brings together high purity excipient technologies, Super Refined™ purification and formulation expertise to help teams support API stability, reduce impurity-driven risk and improve confidence from early formulation challenge through to delivery.

Supporting stability where small molecule APIs are under pressure

Small molecule oncology APIs can be vulnerable to oxidative degradation and excipient - API interactions, both of which can affect formulation stability and performance. Croda’s Super Refined™ technologies are designed to reduce impurities and reactive species that may contribute to degradation, helping formulation teams build a cleaner excipient foundation for sensitive injectable formulations. This can support API stability, reduce impurity-driven risk, strengthen excipient compatibility and improve confidence in performance over time.

Data-led support for oncology formulation decisions

Croda has generated formulation data across small molecule oncology APIs including Docetaxel, Paclitaxel, Etoposide and Fulvestrant. This data helps show how Super Refined™ excipients can support API recovery, reduce degradation and guide more informed excipient choices for oncology injectable applications. For teams working with complex APIs, it creates a clearer link between formulation challenge, product combination and development confidence.
 

Helping address oxidative degradation and excipient-related risk

Commonly used excipients such as polysorbates, PEGs, castor oil derivatives and benzyl alcohol can play important roles in small molecule injectable formulations. However, excipient quality and impurity profile can directly affect formulation performance.

Croda’s Super Refined™ excipients are developed through proprietary purification processes designed to reduce impurities such as peroxides, aldehydes and other reactive species, without changing the chemical composition of the excipient. For example, Super Refined™ Benzyl Alcohol has been used in Fulvestrant-focused stability work, helping demonstrate how higher purity excipients can support API stability and reduce degradation risk in oncology-relevant formulations.

Excipient combinations for complex oncology APIs

Some small molecule oncology formulations require more than a single excipient. The right combination of solubilisers, solvents, surfactants and high purity excipients can help support API stability, solubility and delivery performance. Croda can help formulation teams explore excipient combinations for oncology APIs including:

Docetaxel Potential combinations include Super Refined™ Polysorbate 80, PEG 300 and Propylene Glycol.

Paclitaxel Potential combinations include Super Refined™ Polysorbate 80, P35 Castor Oil, Castor Oil and PEG 300.

Etoposide Potential combinations include Super Refined™ Polysorbate 80, PEG 300 and Benzyl Alcohol.

Fulvestrant Potential combinations include Super Refined™ Benzyl Alcohol, Polysorbate 80 and PEG 300.